182 related articles for article (PubMed ID: 31756977)
1. Repeated Oral Administration of a KDEL-tagged Recombinant Cholera Toxin B Subunit Effectively Mitigates DSS Colitis Despite a Robust Immunogenic Response.
Royal JM; Reeves MA; Matoba N
Toxins (Basel); 2019 Nov; 11(12):. PubMed ID: 31756977
[TBL] [Abstract][Full Text] [Related]
2. A modified cholera toxin B subunit containing an ER retention motif enhances colon epithelial repair
Royal JM; Oh YJ; Grey MJ; Lencer WI; Ronquillo N; Galandiuk S; Matoba N
FASEB J; 2019 Dec; 33(12):13527-13545. PubMed ID: 31560862
[TBL] [Abstract][Full Text] [Related]
3. Oral administration of a recombinant cholera toxin B subunit promotes mucosal healing in the colon.
Baldauf KJ; Royal JM; Kouokam JC; Haribabu B; Jala VR; Yaddanapudi K; Hamorsky KT; Dryden GW; Matoba N
Mucosal Immunol; 2017 Jul; 10(4):887-900. PubMed ID: 27805617
[TBL] [Abstract][Full Text] [Related]
4. Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis.
Blanchard TG; Lycke N; Czinn SJ; Nedrud JG
Immunology; 1998 May; 94(1):22-7. PubMed ID: 9708182
[TBL] [Abstract][Full Text] [Related]
5. Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti-V. cholerae antibody responses in mice.
Ryan ET; Butterton JR; Zhang T; Baker MA; Stanley SL; Calderwood SB
Infect Immun; 1997 Aug; 65(8):3118-25. PubMed ID: 9234763
[TBL] [Abstract][Full Text] [Related]
6. Rapid and scalable plant-based production of a cholera toxin B subunit variant to aid in mass vaccination against cholera outbreaks.
Hamorsky KT; Kouokam JC; Bennett LJ; Baldauf KJ; Kajiura H; Fujiyama K; Matoba N
PLoS Negl Trop Dis; 2013; 7(3):e2046. PubMed ID: 23505583
[TBL] [Abstract][Full Text] [Related]
7. Spray-Dried Formulation of Epicertin, a Recombinant Cholera Toxin B Subunit Variant That Induces Mucosal Healing.
Reeves MA; Royal JM; Morris DA; Jurkiewicz JM; Matoba N; Hamorsky KT
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33919585
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G
Chulkina MM; Pichugin AV; Ataullakhanov RI
Peptides; 2020 Oct; 132():170364. PubMed ID: 32621844
[TBL] [Abstract][Full Text] [Related]
9. Construction of a Vibrio cholerae prototype vaccine strain O395-N1-E1 which accumulates cell-associated cholera toxin B subunit.
Rhie GE; Jung HM; Kim BS; Mekalanos JJ
Vaccine; 2008 Oct; 26(43):5443-8. PubMed ID: 18582519
[TBL] [Abstract][Full Text] [Related]
10. Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli.
Bckström M; Holmgren J; Schödel F; Lebens M
Gene; 1995 Nov; 165(2):163-71. PubMed ID: 8522171
[TBL] [Abstract][Full Text] [Related]
11. Mucosal immunogenicity of a holotoxin-like molecule containing the serine-rich Entamoeba histolytica protein (SREHP) fused to the A2 domain of cholera toxin.
Sultan F; Jin LL; Jobling MG; Holmes RK; Stanley SL
Infect Immun; 1998 Feb; 66(2):462-8. PubMed ID: 9453596
[TBL] [Abstract][Full Text] [Related]
12. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo.
Apter FM; Michetti P; Winner LS; Mack JA; Mekalanos JJ; Neutra MR
Infect Immun; 1993 Dec; 61(12):5279-85. PubMed ID: 8225601
[TBL] [Abstract][Full Text] [Related]
14. Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells.
Ploix C; Bergerot I; Durand A; Czerkinsky C; Holmgren J; Thivolet C
Diabetes; 1999 Nov; 48(11):2150-6. PubMed ID: 10535448
[TBL] [Abstract][Full Text] [Related]
15. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis.
Ungaro R; Fukata M; Hsu D; Hernandez Y; Breglio K; Chen A; Xu R; Sotolongo J; Espana C; Zaias J; Elson G; Mayer L; Kosco-Vilbois M; Abreu MT
Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1167-79. PubMed ID: 19359427
[TBL] [Abstract][Full Text] [Related]
16. Isolation and detection of a KDEL-tagged recombinant cholera toxin B subunit from
Morris DA; Reeves MA; Royal JM; Hamorsky KT; Matoba N
Process Biochem; 2021 Feb; 101():42-49. PubMed ID: 33304198
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of TcpF-A2-CTB chimera and evidence of additive protective efficacy of immunizing with TcpF and CTB in the suckling mouse model of cholera.
Price GA; Holmes RK
PLoS One; 2012; 7(8):e42434. PubMed ID: 22879984
[TBL] [Abstract][Full Text] [Related]
18. Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates.
Bergquist C; Lagergård T; Lindblad M; Holmgren J
Infect Immun; 1995 May; 63(5):2021-5. PubMed ID: 7537252
[TBL] [Abstract][Full Text] [Related]
19. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
Liao J; Gibson JA; Pickering BS; Watnick PI
mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
[TBL] [Abstract][Full Text] [Related]
20. Mucosal vaccines based on the use of cholera toxin B subunit as immunogen and antigen carrier.
Lebens M; Holmgren J
Dev Biol Stand; 1994; 82():215-27. PubMed ID: 7958476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
